Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

Navid, Fariba; Sondel, Paul M.; Barfield, Raymond; Shulkin, Barry L.; Kaufman, Robert A.; Allay, Jim A.; Gan, Jacek; Hutson, Paul; Seo, Songwon; Kim, KyungMann; Goldberg, Jacob; Hank, Jacquelyn A.; Billups, Catherine A.; Wu, Jianrong; Furman, Wayne L.; McGregor, Lisa M.; Otto, Mario; Gillies, Stephen D.; Handgretinger, Rupert; Santana, Victor M.

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

Autor(en):

Navid, Fariba; Sondel, Paul M.; Barfield, Raymond; Shulkin, Barry L.; Kaufman, Robert A.; Allay, Jim A.; Gan, Jacek; Hutson, Paul; Seo, Songwon; Kim, KyungMann; Goldberg, Jacob; Hank, Jacquelyn A.; Billups, Catherine A.; Wu, Jianrong; Furman, Wayne L.; McGregor, Lisa M.; Otto, Mario; Gillies, Stephen D.; Handgretinger, Rupert; Santana, Victor M.

Tübinger Autor(en):

Handgretinger, Rupert

Erschienen in:

Journal of Clinical Oncology (2014), Bd. 32, H. 14, S. 1445-

Verlagsangabe:

Amer Soc Clinical Oncology

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.2013.50.4423

ISSN:

0732-183X